This project involved renovating a previously vacant building within our Philadelphia campus… not only have we added significant pallet capacity for our customers’ large-scale clinical studies today, but have secured the space necessary for future expansion as well.
Somerset, NJ (PRWEB) September 15, 2017
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it is investing $5.5 million at its 200,000+ square foot Philadelphia, Pennsylvania, site to provide additional clinical packaging and storage capacity.
The 22,000-square foot expansion will see a 40 percent increase in pallet space for both refrigerated and ambient storage; the addition of multiple cold chain packaging areas; and a new clinical label control area. The building will also feature a new state-of-the-art environmental monitoring and building management system which is being installed across the Philadelphia campus.
All work is scheduled to be completed and validated by November 2017.
“This project involved renovating a previously vacant building within our Philadelphia campus to bring it up to Catalent’s stringent facility standards,” commented Wetteny Joseph, Catalent’s President, Clinical Supply Services. “Not only have we added significant pallet capacity for our customers’ large-scale clinical studies today, but have secured the space necessary for future expansion as well.”
Catalent currently supports the clinical trial supply needs of many pharmaceutical and biopharmaceutical organizations, including the top 25 pharmaceutical companies, and more than 300 small innovators from all over the world. Services include direct comparator sourcing, blinding and manufacturing, primary and secondary packaging, returns and clinical supplies management.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™